STRYKER 864952 - eine der besten Medizintechnikaktien (Seite 10)
eröffnet am 26.07.06 13:50:26 von
neuester Beitrag 13.02.24 19:17:12 von
neuester Beitrag 13.02.24 19:17:12 von
Beiträge: 456
ID: 1.073.233
ID: 1.073.233
Aufrufe heute: 0
Gesamt: 61.465
Gesamt: 61.465
Aktive User: 0
ISIN: US8636671013 · WKN: 864952 · Symbol: SYK
304,80
EUR
-0,13 %
-0,40 EUR
Letzter Kurs 15:41:36 Tradegate
Neuigkeiten
30.04.24 · globenewswire  |
30.04.24 · wallstreetONLINE Redaktion |
01.04.24 · globenewswire |
26.03.24 · globenewswire |
26.03.24 · Business Wire (dt.) |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,3600 | +72,26 | |
| 8,1400 | +20,41 | |
| 0,8232 | +17,25 | |
| 1,0900 | +15,96 | |
| 0,6600 | +15,79 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5000 | -26,24 | |
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Stryker erhöht die Quartalsdividende von 0,15$ auf 0,18$.
29.10.2010 22:01
Stryker Announces Acquisition of Privately-Held Porex Surgical
KALAMAZOO, Mich., Oct. 29 /PRNewswire-FirstCall/ -- Stryker Corporation announced today the acquisition of privately-held Porex Surgical, a division of Porex Corporation. Porex Surgical is a developer, manufacturer and distributor of bioimplantable porous polyethylene products (PPE) for use primarily in reconstructive surgery of the head and face. Porex has a long history in the PPE market with strong brand recognition and considerable clinical data supported by approximately 350 references in peer-reviewed journals. The product portfolio and customer base complements Stryker's existing offering in the craniomaxillofacial (CMF) market.
"The acquisition of Porex Surgical further expands on our presence in the CMF market and allows us to broaden our product offering to both patients and clinicians," said Stephen P. MacMillan, Chairman, President and Chief Executive Officer of Stryker.
The transaction is expected to be neutral to Stryker's 2010 and 2011 earnings per share and accretive thereafter. Terms of the transaction were not disclosed.
Stryker Announces Acquisition of Privately-Held Porex Surgical
KALAMAZOO, Mich., Oct. 29 /PRNewswire-FirstCall/ -- Stryker Corporation announced today the acquisition of privately-held Porex Surgical, a division of Porex Corporation. Porex Surgical is a developer, manufacturer and distributor of bioimplantable porous polyethylene products (PPE) for use primarily in reconstructive surgery of the head and face. Porex has a long history in the PPE market with strong brand recognition and considerable clinical data supported by approximately 350 references in peer-reviewed journals. The product portfolio and customer base complements Stryker's existing offering in the craniomaxillofacial (CMF) market.
"The acquisition of Porex Surgical further expands on our presence in the CMF market and allows us to broaden our product offering to both patients and clinicians," said Stephen P. MacMillan, Chairman, President and Chief Executive Officer of Stryker.
The transaction is expected to be neutral to Stryker's 2010 and 2011 earnings per share and accretive thereafter. Terms of the transaction were not disclosed.
Stryker: Neurovascular Operations To Return To Market Growth In 2012
Stryker Corp. (SYK) is spending $1.5 billion to buy a neurovascular device business at Boston Scientific Corp. (BSX) that has recently seen declining sales, but Stryker believes the business will get back to market-growth rates by 2012, officials said Thursday.
The Boston Scientific business includes detachable coils used to treat aneurysms. Sales there shrank 3% last year to $348 million, and slipped a steeper 7% in the third quarter due to a delayed product launch and what Boston Scientific recently described as a field action for a different product.
But the overall $900 million market for neurovascular products is growing about 9% to 10%, said Curt Hartman, Stryker's chief financial officer. The company is assuming it can get the business to "marginal growth" next year, and "we think 2012 gets the business back in line with market growth," Hartman said on a conference call Thursday.
Stryker said the all-cash transaction should be break-even to slightly accretive to 2011 earnings per share, excluding certain acquisition and integration-related charges. The company will pay $1.4 billion at closing, seen in December, and then up to $100 million when certain milestones are hit.
Officials at Stryker, which will keep Boston Scientific neurovascular President Mark Paul in place after the business changes hands, didn't indicate problems with how the business is run under current ownership. From 2000 through 2007 it was "on a rocket ship," but then slipped in recent years as Boston Scientific dealt with some quality challenges, said Stephen MacMillan, Stryker's chairman and chief executive. With a key new product recently approved, Stryker said it believes the business is about to turn things around.
"We think they are re-poised for growth now," MacMillan said. "It's a great team that happened to stumble on some broader challenges."
Stryker Corp. (SYK) is spending $1.5 billion to buy a neurovascular device business at Boston Scientific Corp. (BSX) that has recently seen declining sales, but Stryker believes the business will get back to market-growth rates by 2012, officials said Thursday.
The Boston Scientific business includes detachable coils used to treat aneurysms. Sales there shrank 3% last year to $348 million, and slipped a steeper 7% in the third quarter due to a delayed product launch and what Boston Scientific recently described as a field action for a different product.
But the overall $900 million market for neurovascular products is growing about 9% to 10%, said Curt Hartman, Stryker's chief financial officer. The company is assuming it can get the business to "marginal growth" next year, and "we think 2012 gets the business back in line with market growth," Hartman said on a conference call Thursday.
Stryker said the all-cash transaction should be break-even to slightly accretive to 2011 earnings per share, excluding certain acquisition and integration-related charges. The company will pay $1.4 billion at closing, seen in December, and then up to $100 million when certain milestones are hit.
Officials at Stryker, which will keep Boston Scientific neurovascular President Mark Paul in place after the business changes hands, didn't indicate problems with how the business is run under current ownership. From 2000 through 2007 it was "on a rocket ship," but then slipped in recent years as Boston Scientific dealt with some quality challenges, said Stephen MacMillan, Stryker's chairman and chief executive. With a key new product recently approved, Stryker said it believes the business is about to turn things around.
"We think they are re-poised for growth now," MacMillan said. "It's a great team that happened to stumble on some broader challenges."
Stryker Corp. to buy Boston Scientific division
Stryker Corp. to pay up to $1.5 billion for Boston Scientific neurovascular division
KALAMAZOO, Mich. (AP) -- Stryker Corp. said Thursday it will pay up to $1.5 billion to buy the neurovascular division of fellow medical device maker Boston Scientific.
Boston Scientific shares jumped in pre-market trading on the news.
Stryker plans to pay $1.4 billion at the deal's closing and then up to $100 million in milestone payments. The deal is expected to close in the fourth quarter.
Boston Scientific, based in Natick, Mass., will receive the milestone payments for the commercialization of the next-generation Target detachable coils, which are used to treat hemorrhagic strokes, and for the transfer of some manufacturing facilities.
Its neurovascular division is based in Fremont, Calif., employs about 1,150 people and had $348 million in sales last year. It makes detachable coils, stents and other devices used to treat brain aneurysms and other types of cerebrovascular disease.
Stents are mesh-metal tubes that hold arteries open after blood vessels are surgically cleared of plaque. Coils are used to fill and seal aneurysms.
Boston Scientific Neurovascular President Mark Paul will head the Stryker Neurovascular business.
Stryker, based in Kalamazoo, Mich., said the deal is expected to be neutral or add slightly to its earnings per share next year, excluding certain charges.
Stryker Corp. to pay up to $1.5 billion for Boston Scientific neurovascular division
KALAMAZOO, Mich. (AP) -- Stryker Corp. said Thursday it will pay up to $1.5 billion to buy the neurovascular division of fellow medical device maker Boston Scientific.
Boston Scientific shares jumped in pre-market trading on the news.
Stryker plans to pay $1.4 billion at the deal's closing and then up to $100 million in milestone payments. The deal is expected to close in the fourth quarter.
Boston Scientific, based in Natick, Mass., will receive the milestone payments for the commercialization of the next-generation Target detachable coils, which are used to treat hemorrhagic strokes, and for the transfer of some manufacturing facilities.
Its neurovascular division is based in Fremont, Calif., employs about 1,150 people and had $348 million in sales last year. It makes detachable coils, stents and other devices used to treat brain aneurysms and other types of cerebrovascular disease.
Stents are mesh-metal tubes that hold arteries open after blood vessels are surgically cleared of plaque. Coils are used to fill and seal aneurysms.
Boston Scientific Neurovascular President Mark Paul will head the Stryker Neurovascular business.
Stryker, based in Kalamazoo, Mich., said the deal is expected to be neutral or add slightly to its earnings per share next year, excluding certain charges.
Antwort auf Beitrag Nr.: 40.354.121 von Ulf-Imat am 19.10.10 23:35:06Du warst schneller als ich 
19.10.2010 23:33
UPDATE 2-Stryker profit beats forecast, shares rise
NEW YORK, Oct 19 (Reuters) - Stryker Corp on Tuesday reported stronger-than-expected quarterly earnings, helped by a tax benefit, asset sales and strong shipments of its surgical equipment, sending shares more than 4 percent higher.
Given favorable current trends, Stryker said it now expects full-year sales to grow 7 to 8 percent, from its prior forecast of 5 to 8 percent growth, excluding the impact of foreign currency fluctuations.
Third-quarter net income was $338 million, or 85 cents per share, compared with $229 million, or 57 cents a share, a year ago.
Excluding special items, including a $13 million gain from selling a factory in France and a $7 million tax benefit, Stryker said it earned 80 cents a share. Analysts on average expected 77 cents per share, according to Thomson Reuters I/B/E/S.
Sales rose 6.9 percent to $1.77 billion, coming in a bit higher than Wall Street expectations of $1.75 billion. Revenue would have grown 7 percent if not for foreign currency factors, the company said.
U.S. sales rose 9.7 percent to $1.17 billion as a result of higher shipments of orthopedic implants and MedSurg equipment. Overseas sales rose 1.7 percent to $594 million.
Global sales of orthopedic implants rose 1.2 percent to $1.03 billion, on stronger U.S. sales of hip replacements, knee replacements and trauma implant systems.
Sales of MedSurg equipment jumped 16.1 percent to $739 million, on higher shipments of surgical equipment and surgical navigation systems, endoscopic and communication systems, as well as through acquisitions, the company said.
Shares of the Kalamazoo, Michigan-based company rose to $52.75 from their closing price of $50.51 Tuesday on the New York Stock Exchange.
19.10.2010 23:33
UPDATE 2-Stryker profit beats forecast, shares rise
NEW YORK, Oct 19 (Reuters) - Stryker Corp on Tuesday reported stronger-than-expected quarterly earnings, helped by a tax benefit, asset sales and strong shipments of its surgical equipment, sending shares more than 4 percent higher.
Given favorable current trends, Stryker said it now expects full-year sales to grow 7 to 8 percent, from its prior forecast of 5 to 8 percent growth, excluding the impact of foreign currency fluctuations.
Third-quarter net income was $338 million, or 85 cents per share, compared with $229 million, or 57 cents a share, a year ago.
Excluding special items, including a $13 million gain from selling a factory in France and a $7 million tax benefit, Stryker said it earned 80 cents a share. Analysts on average expected 77 cents per share, according to Thomson Reuters I/B/E/S.
Sales rose 6.9 percent to $1.77 billion, coming in a bit higher than Wall Street expectations of $1.75 billion. Revenue would have grown 7 percent if not for foreign currency factors, the company said.
U.S. sales rose 9.7 percent to $1.17 billion as a result of higher shipments of orthopedic implants and MedSurg equipment. Overseas sales rose 1.7 percent to $594 million.
Global sales of orthopedic implants rose 1.2 percent to $1.03 billion, on stronger U.S. sales of hip replacements, knee replacements and trauma implant systems.
Sales of MedSurg equipment jumped 16.1 percent to $739 million, on higher shipments of surgical equipment and surgical navigation systems, endoscopic and communication systems, as well as through acquisitions, the company said.
Shares of the Kalamazoo, Michigan-based company rose to $52.75 from their closing price of $50.51 Tuesday on the New York Stock Exchange.
Trading Spotlight
!
Dieser Beitrag wurde moderiert. Grund: auf eigenen Wunsch des Users
15.09.2010 18:32
Stryker Declares a $0.15 Per Share Quarterly Dividend
KALAMAZOO, Mich., Sept. 15 /PRNewswire-FirstCall/ -- Stryker Corporation announced today that its Board of Directors has declared a quarterly dividend of $0.15 per share payable on October 29, 2010, to shareholders of record at the close of business on September 30, 2010.
Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company provides innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people lead more active and more satisfying lives.
Stryker Declares a $0.15 Per Share Quarterly Dividend
KALAMAZOO, Mich., Sept. 15 /PRNewswire-FirstCall/ -- Stryker Corporation announced today that its Board of Directors has declared a quarterly dividend of $0.15 per share payable on October 29, 2010, to shareholders of record at the close of business on September 30, 2010.
Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company provides innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people lead more active and more satisfying lives.
Stryker buys Gaymar Industries for $150 million
Medical device maker Stryker Corp. said Wednesday it agreed to buy privately held Gaymar Industries for $150 million in cash.
The boards of both companies have approved the sale, which is expected to close by Oct. 1.
Stryker, which makes hip and knee implants and other orthopedic devices and surgical equipment, said the deal was expected to have no impact in Stryker's 2010 and 2011 earnings per share but to increase earnings in later years.
Gaymar is owned by private equity firms Nautic Partners and Norwest Equity Partners. It had sales of about $77 million last year. About $14 million came from a deal with Stryker -- Gaymar gave Stryker rights to sell products to treat pressure ulcers and other conditions to acute-care customers in North America.
Stryker said the acquisition fit its goal of expanding product offerings.
Medical device maker Stryker Corp. said Wednesday it agreed to buy privately held Gaymar Industries for $150 million in cash.
The boards of both companies have approved the sale, which is expected to close by Oct. 1.
Stryker, which makes hip and knee implants and other orthopedic devices and surgical equipment, said the deal was expected to have no impact in Stryker's 2010 and 2011 earnings per share but to increase earnings in later years.
Gaymar is owned by private equity firms Nautic Partners and Norwest Equity Partners. It had sales of about $77 million last year. About $14 million came from a deal with Stryker -- Gaymar gave Stryker rights to sell products to treat pressure ulcers and other conditions to acute-care customers in North America.
Stryker said the acquisition fit its goal of expanding product offerings.
Antwort auf Beitrag Nr.: 39.856.602 von thetoto am 21.07.10 17:52:41Conference Call gibt es auf SeekingAlpha.
Knie- und Hüftprotesen waren hinter den Erwartungen, sollen aber durch neue Produkte in Zukunft wieder ausgeglichen werden. Einige alte Produkte wurden aus dem Segment genommen, was sich negativ auf den Umsatz, aber positiv auf die Margen ausgewirkt hat.
Der Trend sei aber nach wie vor positiv, die Jahresprognose wurde nochmals bestätigt.
EpS zum Vorjahr knapp unter +10%, Umsatz nur +8%. Bei der Cashposition finde ich Stryker weiterhin einen guten Kauf.
Knie- und Hüftprotesen waren hinter den Erwartungen, sollen aber durch neue Produkte in Zukunft wieder ausgeglichen werden. Einige alte Produkte wurden aus dem Segment genommen, was sich negativ auf den Umsatz, aber positiv auf die Margen ausgewirkt hat.
Der Trend sei aber nach wie vor positiv, die Jahresprognose wurde nochmals bestätigt.
EpS zum Vorjahr knapp unter +10%, Umsatz nur +8%. Bei der Cashposition finde ich Stryker weiterhin einen guten Kauf.
Durchsuchen
30.04.24 · wallstreetONLINE Redaktion · Air Liquide |
26.03.24 · Business Wire (dt.) · Stryker |
21.03.24 · wallstreetONLINE Redaktion · Air Liquide |
28.02.24 · Business Wire (dt.) · Stryker |